STRA13 Antibody (FITC)

Background

STRA13, also known as CENPX, is a member of the basic helix-loop-helix (bHLH) family of transcription factors. STRA13 is upregulated in response to retinoic acid, hypoxia, and other cellular stress signals, where it functions as a transcriptional repressor or activator depending on its interaction partners. It regulates processes such as cell cycle progression, apoptosis, immune responses, and metabolic pathways. STRA13 plays a crucial role in hypoxia-inducible factor (HIF)-mediated responses by suppressing cell proliferation and modulating oxygen-dependent pathways. It is highly expressed in immune cells, cancer tissues, and hypoxic environments, where it controls inflammatory cytokine production and enhances cellular survival under low oxygen. Dysregulation of STRA13 is associated with cancer progression, immune dysregulation, and metabolic disorders. Loss-of-function studies reveal defects in immune regulation, impaired response to hypoxia, and abnormal cell proliferation, emphasizing its role in stress adaptation, transcriptional regulation, and homeostasis maintenance.